Oaktree Acquisition Corp. III Life Sciences (OACCU) Prices $175M IPO

Oaktree Acquisition Corp. III Life Sciences announced the pricing of its $175 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “OACCU”, Thursday, October 24, 2024.

The new SPAC plans to combine with a healthcare target or one in a healthcare-related industry in North America or Europe.

The sponsor team for Oaktree III is to be led by Chairman John Frank, Chief Executive Officer Zaid Pardesi, Chief Operating Officer Mathew Pendo, and Chief Financial Officer Courtney Conigliaro. Its Board is to be made up of Aman Kumar, Paul Meister and Alvin Shih.

Total SPAC deal count for 2024 year-to-date is now 39. This offering is expected to close on Friday, October 25, 2024.

Jefferies, Citigroup Global Markets Inc., and UBS Securities LLC are serving as the joint book-running managers for the offering. Kirkland & Ellis LLP is serving as Issuer’s Counsel with White & Case LLP serving as Underwriter’s Counsel. WithumSmith+Brown, PC serves as auditor. Continental Stock Transfer & Trust Company is acting as trustee.